(12) 4 34tt RAIS AOL AEA S 1BR
`
`(19) HERSO AS AT HeA
`HRSA
`
`(43) BIRGRA
`2004 4F3 A4 A (04.03.2004)
`
` (10) BRAHMS Ss
`
`WO 2004/017973 Al
`
`(51) BRR st 3 HB’:
`AG61P 25/18 // COTD 417/12
`
`A61K 31/496,
`
`(21) BROS S:
`
`PCT/JP2003/010490
`
`(22) ERR RA:
`
`2003 4£8 A20 A (20.08.2003)
`
`(25) ERR WR Se:
`
`(26) BIRR ABA Bee:
`
`(30) BAET—4:
`60/404,927
`
`AA
`
`AA
`
`2002 4E8 A 22 A (22.08.2002)
`
`US
`
`(71) WRBA (KABER<K SCOREBIXDUT): ER
`sal SEE Ste tt (SUMITOMO PHARMACEUTICALS
`COMPANY,LIMITED)[JP/JP]; 541-8510 AMRAF XK
`Bari ph REE HT2T A 2285 Osaka(IP).
`
`(72) FHA; SKU
`(75) FFAS/MBA (KEI DU COA): PH =F (NAKA-
`MURA,Mitsutaka) [JP/JP]; 7541-0045 KBRAT KPA
`RBIS2T A238 ERMASLA Osaka
`(JP). 4 BR (OGASA,Masaaki) [JP/JP]; T 541-0045
`AR Ath $REGEN2T A2B85 ERM
`eat SFt A Osaka (IP). 20 4 St (SAMI,Shunsuke)
`[JP/JP]; 7541-0045 KiAF Aik PRR BBAT2T
`A288 (ESat St W Osaka(IP).
`
`(74) IBA: EO, 9}(CKXAWAMIYA,Osamuet al.); T
`540-0001 AAT Aikrh PRRRMA1T B3B7S1MP
`ko ob ET LU BSA Osaka (JP).
`
`(81) 485€H (BIA): AE, AG, AL, AM,AT, AU, AZ, BA, BB,
`BG,BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,
`DM,DZ,EC,EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
`ID, IL, IN,IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
`LU,LV, MA, MD, MG, MK, MN, MW, MX, MZ,NI, NO,
`NZ, OM,PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
`SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
`VN, YU, ZA, ZM, ZW.
`
`(84) #85e HB (ik): ARIPO #434 (GH, GM, KE, LS, MW, MZ,
`SD, SL, SZ, TZ, UG, ZM, ZW), 1-3 YF (AM,
`AZ, BY, KG, KZ, MD, RU, TJ, TM), 3—O wy s\ 4
`(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
`GR, HU,IE, IT, LU, MC, NL, PT, RO,SE, SI, SK, TR),
`OAPI #43 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
`ML,MR,NE, SN, TD, TG).
`
`RAS A:
`RRS RAaS
`
`2MFI—FRUMHOMBIANDUTCIA, EHRAENS
`SPCTH Hy FORBITEBMENTUS TI— FER
`OH4FVYA/—+b) eB.
`
`(54) Title: REMEDY FOR INTEGRATION DYSFUNCTION SYNDROME
`
`(54) HAOZM: Ra RAEARAl
`
`
`
`ACL|IAAYANIMUIOOTUTAAA
`
`(57) Abstract: It is intended to provide a novel methodoftreating integration dysfunction syndrome. Namely, 5 mg to 120 mg/day of
`7) an active compound (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1 ,2-benzoisothiazol-3-yl)- 1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bi-
`E~ cyclo[2.2.1]heptane dicarboxyimide or its pharmaceutically acceptablesalt (for example, hydrochloride) is orally administered to a
`patient with integration dysfunction syndrome once a day. According to this method, broad symptomsofintegration dysfunction
`syndrome, in particular, positive symptoms and negative symptoms, can be ameliorated without causing any extrapyramidal reac-
`eS tions.
`
`179
`2004/ (57) BH: MARAE OMMERRAKERHETSZAEDCHPrPC. BHEtKAWELT
`
`(1R,28,3R,4S)-N-[(1R,2R}2-[4-(1, 2-44 VFP VIL 8-4 WL) 1 -E RS VAIS FILE I1-
`VIONLYILAF ILE 2, 3-EVIO[2.2.1]NFTaV VARA FE FERMSZEORBRELHAB EN SHA
`©} if, BBE. 1BRBSBSme~120meiitibi, RABE BSICBORSTAZCEICEY,
`HANRARIVAORPBZEHE DICER“ PMARBEOMAUEK, RIKLBREKEBKEUEBEEKEKET S
`s CéEMCSSMARMEORRAK,. ZOUtHIACAYSARA,
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 001
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 001
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`EXONADBP
`
`ARSERAIL, BLMARAEOIRRTIEK LOVGRAITET 5, SOITHLS
`
`(kL, ASISEIEO EY ANTSAYVINK2 PPRAOMERS 1 A
`
`LMREORSTSU LICE, GEMSMAABER ORESED CLS. MAK
`
`PE COUCHES SHER KOCHITAW SIGRANTES.
`
`10
`
`PBT
`
`GERI (HRDSYR, schizophrenia) lt, ARMEBSHHAO 1 EC. ELL
`
`CHEMIL. BHORIEZ EEO, RBICAROMRBRe SUT. CO
`
`ERITH ILEOIRBCh O, HERE LCI, SEOMRICS< LONSSE
`
`15
`
`VBA EOGHEROIED, RITCCSERABRE LEBER, BHACSE
`
`(CES SRBAMERKREBHS, S OITTOUMUREKE UTI OIER, FRE
`
`TREbKHS,
`
`CL OKMGRAEOIPRITIL, boILSRMRED L OITWSR, RICHO
`
`CHEERS DECh 0, EKAIGMLKBACHRETILDOS LBET Siar
`
`20
`
`RE <. WCE CORMRE Si SVERBHS, CORD, RMREICL SOA
`
`(EOL 720, PPSERDPORMEHORV, RMRE b ARERRRE
`
`V4.
`
`BEIOIE L UCL, AARCDS SX OR, HIZIL, 7
`
`UMP AVLIY, AARVSAVVYYSOFT 2) FT VYGRE 7 I FTV
`
`20
`
`VCLIABER ET SUNT AFH AY, PVAYFEYNEOFAS
`
`PUP UB, AVEV RL AVETU REORY AT ® RIA, 2 OFT
`
`Bl. EFY FG AEOFLI VI ECUPBAREBSY, SHI, ABRU PR
`
`—y, KUNRY Poe POFF AI a) VBR, CPEV PEO IZ ecanT
`
`FVST 2 VBR, 2EBX OBMMBAV SINWS,
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 002
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 002
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`2
`
`LOELRB BS, PIRI, FeO FTUU, Fe IFT VVULE,
`
`SHaA7 x) VFBARE CS, BEREMER LC UC. RRA L. ICE
`
`BAH, BALIHAT ONE Y DIREREET 3 OES
`
`SME AREREREED, VI 2STFNS & VRPRIIRIRIEOIED, BEARS
`ATR EHO P CE BhS, EKO SRFOMMPRRIL, MaAMEICSIT
`SRPERETK, KEPERETK, BAVERO 5b, —RORERICILAWCHSBTRTTO
`
`HEIKO L COREIET S 6 OIL,
`
`LEO. UHL LCOMBARIEICH LCENEMREATS &
`
`FEC, SEASMER ATEIREEO 5 RRIF ORVREREWORBOBEVWS,
`
`10
`
`Hh, AIHADOMMES ITE D WM Stic FRORRCR SNS SRE
`
`(ADS. PUBAUSECRRETRE, PIRRED. & < Cera, BEATA
`
`BA, 77aeSOIRRAIL UCHR EBM SNWSCREE
`
`5,532,372),
`
`AP
`DV
`G-A
`Z—D-N
`\_/
`
`15
`
`su, Ztask:
`
`O
`
`(CHa),
`R!
`N—
`2
`
`R —B
`3
`R"
`R4
`
`Drs: —(CH,),-A-(CH,),—-. Glk%
`
`N—
`
`‘cu
` . ERIM & Arik
`
`FSR, FFERARE,
`
`20
`
`SE ORE
`
`ARSEIL, BMARHEOIRICENKMREA LL. Li biEKOBe
`
`DBS ICH IVS BEARS iEBRHE 78 UEORIVEFR AS 72 << REICHSD TYAB Ze
`
`of LVYARRAIS BLISS << , HOT 3 BRBREIRIZOVC, FOR, ARSE
`
`CREORE Boke, Pats:
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 003
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 003
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`(1)
`
`oy ‘s
`
`GRENS(1R,28,3R,4S)-N-[(1R, 2R)-2-[4-(1, 2-—“~v
`
`YA YVFI YN 8B -A NM) - 1TH ERG VENA FN) - 1-H
`
`AFVI—2,38-EVA7Al2. 2.1AARVVANHEVS & PEKO
`
`Wii 72 U OESLFA SN OHS, POGARTE LCHRIAY TERORBOIRS
`
`AL. £OMEEBS LALARARSTSI LICKED, SEAOMRARIE eS
`
`CER. HD CRAIC MAAME BIR LHS Ob eH LE.
`
`oie b, AHA Les (1) CRSMNS (LR, 28,3R,48S)-N-[(1
`
`R, 2R)—-2—-[4—-(1, 2-NvYV VY4 VF TYNn 8-40) -1- PRY
`
`10
`
`av RFU] -— LAH FanevrAFW)-—2,383-EYV7aAl2.2.1jIn7?
`
`VU AMRF 2 PERMEOBRLAA SN6HOMERt MARMESS
`
`ICL A LEER RSETSO ELD, GEARREIVFR ORES Cb e<,
`
`BEAARE LIBRSAIK, ROUICENMCHAVSIRRAIZERET Sb OTCHS,
`
`15
`
`Pai © fii BALAA
`
`BLSBSR LORRRRICKI 5. RRM OWE(LAWO(LR, 28,
`
`3R,4S)-N-[(1R, 2R)—2-[4—-(1, 2-"vYY4 VF TY—N- 8
`
`—4 IVY) 1H ERG VaAF) A- LAH aneYAFI] -2,38-EY
`
`JALZ.2.1IAPFVYVANHREYAT S PHBLUA AF EMRITE SHAK
`
`20
`
`AEST SORORECh SADRHERRMRE Brief Psychiatric
`
`Rating Scale: BPRS)OABST OREAILERLET IT CS,
`
`385A OFM72BAA
`
`ASEM SOI, (1R,25,3R,4S)-N-[(1R, 2R)—-2-[4-(1, 2
`
`29
`
`KAY YA YFP YN 38-4) - LK PERF Pan eAFr)]-1- yas
`
`HYMAFN]—-2, 8-72. 2.1LINARVY VANESD PE
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 004
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 004
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`4
`
`BAVC, BeeRMCRT ESIC, BUSES b> OMAAEBA ICT LT
`
`PERS 1 ALG WR ORS LEAL OA, RVVERICH CENARE
`
`BPA LI, BC AKI LI, BAOMMPEIC LENS E45 PRESSAB
`
`VER DIB LRD DIF, PRIC. BEEO APSR IT LID LISHED BNSFEAD
`
`Pps DEM DROSNT, kd TRAITPIAAREOITAFES &
`
`be Wi Le.
`
`ye b, AHABAK(1) CHRSNS (LR, 28, 3R,4S)-N-
`
`[(1R, 2R)—2—-[4—-(1, 2-AYV YA VFTYN38 -AN)-1-ES
`
`GVSMVAFNV]-1L-VI ANEYVRAFNV) -—2,3-EYV7ua[2.2.1]6
`
`10
`
`PRVVDNREVS F PERMLOBRLAA SNS, RICOPER
`
`BIAREO ESIC UCLA LER RSETSO LICE, GASB
`
`FROSPBEES CE 7e<. BBE, BUBIEKK, BAEK 72 CIRiEAa,
`
`& < CBHI£ UBEROU DK ET. OH LVBAKED IRATE
`
`REAKT 5 bO CHS,
`
`15
`
`ASEM, ET. DP SHAG OPMIPRA EET 5 OO CHS,
`
`ASAI LHIE, (1R, 2S, 3R,4S)—-N—-[(1R, 2R)-2-[4-(1,
`
`2Z—-RYSAV FF YN 8-4NM) - 1 HERI VENAFN)-1-V74
`
`NEYVAFINI-2,38 -EV7AL2.2. ASR YVANHEHUDPRK
`
`EOBRERR SNS (BIZIL, Ee, LARS ome~1 20m_~,
`
`20
`
`BRELSIUE1LOme~1OOmeg, SHIBELSIE2Omeg~8 Omg OHe
`
`IMCLALARARSTSI EICLY, MAAMEOMRAVERICH LCEvie
`
`eR SNS, Lab, RRHOMRATKIC LM, NF Y VIR
`
`KK. VARY T, TAY VYTSORMMMERAMEAS. DRPRES
`
`HEORMERDBERBO ONT, XDOCREC, RAVPRICOBLTWS,
`
`20
`
`7233, EHEHOMAAHEOREIOBAT SBAlcI, LINEPLAWORS
`
`BE CH SPUD RVECHERRIES 0, PPSBAITIL WF
`
`FEAwO1L ARSE ome~8 Omg, FEL<lt5meg~60mg, S5
`
`HEELS IEL Ome ~ 4 Ome OMMACI A LARORSTS,
`
`LACE OMAAE OIRTIEICAV ON SIARAlIL, BRL (1) CRS
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 005
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 005
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`5
`
`NS(LAWERIMIE ORBEA SNS, HIT(LR, 2S, 3R,4S)-N—
`
`[(1R, 2R)—-2-[4—-(1, 2-48vV YA YFP YN 8-47) -1-EN
`
`GVEMAFVI-A- VI anseyvrzAFNW)\—2,3-Ev7ul2.2,1]~s
`
`PEYVANMREYA > RRS, REMMSEY omg~1 20mg, ME
`
`L<tk1 Omg~1O00meg, SH5IMELSIE2 Omg~8 Omg, OHEBT
`
`SAT ARORA CHS, MORALE UCGEA, FRA, ARALAI, BORA
`
`ATEN, VAEvAASRBeTSnS, Midis 1 A LARSAA
`
`ETS,
`
`EAA, OSH DORRAIOMMICAV ONS RSLS SOE
`
`10
`
`tk, PIZIE, FL, BWR PROB FU UYRBAUA, WAVY,
`
`WV, eeVaA, ABR EOWA, 7K. BAIEDF YY, AW
`
`MIAEVAFIVEVA- A, EA VI, AFKFMENUA-A, TAFETAL, IW
`
`YR RU CHNVEAY PYREORRAL TUEORT hUUAL AYTY
`
`HK. PITIVR, RBKRITbUU AD. HU AHYEF LY YES VAR
`
`15
`
`DAFMVE FOU VHRRT bh UDA. APP U VERE TU EY PE CORE
`
`Al BRAND, ATTY VB. ROMER, RU TF UY TV ave LOR
`
`RANE LEAVY C RIBITHE o CHR SVS,
`
`FRB
`
`20
`
`DETR SEISCABOWES LOMRITOWT E SICAAMT
`
`BTS.
`
`7pis, SERGI CHV RIEHHLAWSM—-13496&Ik (1R,2S,3R,4
`
`S)-N-[(1R, 2R)—2—-[4-(1, 2-—"YY 4 VY FT Y—N- 3-7)
`
`— [HERS VaNVAFM LHI AREYAF) - 2, 3-EvV7 (2.
`
`25
`
`Q.1]IAAPRPVY VINEEFT SRSBRL, SRO POMELTHOR
`
`DSM-IV: Diagnostic and Statistical Manual of Mental Disorders,
`
`30
`
`CGI—S:
`
`4th ed.
`CAPR ODUR L Biay = = 7 VE 4 HD)
`Clinical Global Impressions scale-Severity of Illness
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 006
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 006
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`CGI-TI:
`
`AIMS:
`
`EPS:
`
`LOCF:
`
`10
`
`BAS:
`
`SAS:
`
`15
`
`PANSS:
`
`6
`
`(GPRARESBeeBAASBE)
`Clinical Global Impressions scale-Improvement
`(RRREAREDRBEE)
`Abnormal Involuntary Movement Scale
`(RRRNE)
`Extrapyramidal symptoms
`(SEARSMESTEA)
`Last Observation Carried Forward
`(LOC FART : FHIASA CEBAILENLARTORTH
`FAW SAN)
`
`Barnes Akathisia Scale
`(FOVSTPRE)
`
`Simpson-Angust Rating Scale
`(SEARSLES ABIEARPREE)
`Positive and Negative Syndrome Scale
`(BSRE + EMERREE)
`
`SERB 1
`
`BUTE1 LPR RRAAR
`
`(1) RRA
`
`20
`
`PRO 1 CARTAIT LD, ORE 1 SHRITKU S14 9 MOMBKMERE
`EMAL LC, EECTS 7 FERROBSRARESilk ST
`PRBRCEY Vava7 yb (washout)#%&, SM—-13496 40mg XMitl
`
`20mg, HL<SMUIURELA LAS BARA RS LARORMERVEE
`
`ze Rat Lc.
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 007
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 007
`
`

`

`RA
`en- 7) TAREE AHR Ee UCR CHIT LEB
`
`
`
`
`
`GFHEERO
`GEA BEE
`
`
`
`
`
`
`
`
`
`WO 2004/017973
`
`PCT/JP2003/010490
`
`#1
`
`
`
`ACESEMD, DSM-IVTERE EL ORAARERRICBC, SME
`13496 -#SE-BICL SO, (HER REA. BERSE, T7 EAR
`
`Re, UTR, GMOS, RSHERLOBATERR
`
`PESBH ORERIVER (DSM-IV) (Od SAERORSE
`
`HEICOVYC, PIERAMHRE KCBSRULE EO RN
`
`TS.
`
`BERIE
`
`
`1) DSM-IVTEIC LARAAEBCOEEHO bO
`
`
`
`
`2) Extracted-BPRSA=742UEAOCGI~SABTAUE
`3) Simpson-Angust’ = 7 2iOA IMS AAT 3 Rh
`4) FRIEDE
`
`
`5)
`1L18~64RO#Be
`
`
`BROKE
`
`
`
`
`1) JERrEORARHER
`2) FARAHARO RECLRAMAT & Be
`3) BRR ORBe
`
`
`4) NOE Y YU, FYDA IR, SE, ERR, TA
`PAUBE
`
`
`5) KebONESR LTV) S BIBBHEO SHO, FL PORS
`6) SAE ARTaT
`
`
`
`RTPY |S PAAR + ARPaie + SETI - ER
`
`
`
`Roe - RSF 4Ome/H, 120meg/HRAFFERE1 ALAC RIM OR
`iB
`5.
`
`
`LARGIR 3 HOFFTERREIZEV GFA Th,
`
`TAvay 7 beROBE 2LAB
`
`
`
`
`1) LOTHAR OGF Ti72V\, SUREARRANLo
`WSBRbR< &b 3 AGEDA)MILER(FRA OD st
`Ya7 7 PHIRET S.
`
`
`2) SEASUTEIRASEEL LIBR IIENOE VY PROPER Te
`
`
`®o
`3) 7FMRDHBLLEBAICIL FT BADER S,
`
`
`StHRE : 1 3 2Q2PI(VFER, 40mg, 120mg E584 46)
`
`
`PARRTRF: 14 OPI(SPA EARSEH 5 OB, 4 OmeSFE5 0
`
`
`fl, L20mg RSH 4 9 fi)
`
`
`
`AE : PANSS, Extracted-BPRS, CGI-S/I
`
`
`
`Feett : EPS Rating scale(Simpson-Angus, Barnes, AIMS), 7° 4 )V
`
`
`4Y(fh, LEE. HIE. 1 2 BER, BRRRE
`
`
`Cie, RAR, SOP FL, RR
`
`
`4) . WPAISER, IRE:TBR, ASR
`
`
`
`
`(2)ERA
`
`1) AE ORih
`
`(i FRRRATHIZB SBPRSBHEUPANS SK3F(LOCF)RBEUIZC
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 008
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 008
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`8
`
`GI-S#BILOCGI-IABRV(LOCE)®, 4Hen#2BLVUE Blo,
`
`RABLUEIMPSHMSHRLEIM, SM-13496 40mgRU1 20m
`
`g ReSRORRETH(RSE 6D)CHU SRSMDOOAATBYEBP
`
`RS, CGI-IRUCG1~—SHiRHiRBW CT, SRERREHO SHE heL
`
`CistatSAICAREO, ERPANS SAC, MRKTHICKU S SM—
`
`13496 120mgRS5ROAZAT RD BT 7 ERREHROCH Lim
`
`WIZARRESRSN, SM-1349 6 LSRHERKOKEDRY DN.
`
`#2
`
`Ree
`
`(PEREBO
`
`
`
`PIER
`
`SM-13496 40 mg
`
`SN-13496 120 mg
`
`(45)
`
`(47)
`
`(44)
`
`
`
` BPRS
`
`
`
`~4.0
`
`~10. 0
`
`
`“14.1
`~b. 8
`PANSS
`
`(23. 10)
`(14. 06)
`GHAaAy
`
`-11.3
`
`
`
`0. 063
`,
`
`#: Tiy{fll Dunnett’ s tHE (BABRL ST ERE LE OLnBR
`Hi, REBAR, RSCHBSL LEEORO
`
`)
`
`
`
`#3
`
`
`
`
`
`
`
`
`0. 002
`0. 004
`CGI-Ss
`
`
`
`
`amr|3% (sp)|328) (SD) 324 (SD)
`
`
`
`0.0 (0.77)|-0.7 (1. 12) -0.8 (1.03)
`
`(n=41)
`
`(n=41)
`
`(n=40)
`
`CGI-I
`
`(n=45)
`
`(n=47)
`
`4,0 (1.41)
`
`3.2 (1. 56)
`
`0. 013
`
`(n=42)
`
`
`
`3.0 (1. 29)
`
`0.005
`
`H: TVAAR yb tHE (REBE De BE & @EERE)
`eR, RSA, RSAETLRESL LEEDROW
`(i i)EK, BPRS##HAAT (LOCF) O#BETI 7icAT Lb, WHOM
`
`10
`
`LICRT LID CHS, M1lcRT ERY, SM-134968R5HicCBIS
`
`BPRSABRTORSGAMDOOBYDBIL, S72 RRS & RL QIN A Pb
`
`ealANCATE REAR BATE (p<0. 05),
`
`(ii i)S6iz, BRKTRCBUSBPR SODA 2 OYLEBL<S ICG
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 009
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 009
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`9
`
`I-11 RLL2ERLERE (VARY S—-) ORPSREAICRT, B45
`
`SDPREIIZ, SM-13496 40mgRU1 20meKhSHLIFERR
`
`GEE CiplaFANT ARREDBYD bIVIE,
`
`#4.
`
`REE
`
`PEERBO
`
`
`
`
`
`SPER
`
`(45)
`
`(47)
`
`(44)
`
`SM-13496 40 mg
`
`SM-13496 120 mg
`
`
`
`
`
`H: Higay 2as L7& Cochran-Mantel-Haenszel BARE (SAAB & PS NHL OLE)
`2) REVEORMM
`
`Ci) LOMUELOBEITHRY SNKASBRE PaOITAT,
`
`#5
`
`CC—C*dSe
`paar|co||
`
`ELE OAHRIEL OO)
`
`ABERD 1 RUBE HkLI)
`
`ABERIEBAR (%)
`
`HEAR
`
`ma
`
`&Hit
`
`PRYDSP
`
`PEPE RV (HUGE RC)
`
`St
`
`(GAR
`
`&
`Hoe
`
`6 (12)
`
`5 (10)
`
`5 (10)
`
`9 (18)
`
`3 @)
`
`6 (12)
`
`2 (A)
`
`es
`
`3 (6)
`
`7 (4)
`
`5 (10)
`
`7
`
`(14)
`
`5 (10)
`
`1 @)
`
`GROASBRIBY ONCEL VOY ELE,
`KSITRANSERY, 149AF11461(7 7%) CHBSRAaDBYOONE
`
`OD. HEA LBBRENIPSECHok, ASHRIZESAPILGIASM—1 34
`
`10
`
`9 6 REOMR CTI VERERLEYbEB< BOONE,
`
`ERABSHAL, GB WR, TRL TOUT, REDE (REE
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 010
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 010
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`10
`
`EIR<) Chok, BRIT 7ER. SM—-13496 40mg, 120mek
`
`GRECENEMN1 OR, 18%, LAWTBDO SN, MAITSM—-13496
`
`120mg 5-HChORICILRHEE Ch OEMS, WER EIST ST 2 RRS
`
`LU DRDO, HHOWRBISM—-13496 40mgRU120meg
`
`PeG-BE(4 YRU2%)CHP EHR(10%) LYUDRPOK, TAYYT IS
`
`SM—-1349 6RSHCOLBY ON, 40megkOl 20meR5H CoH
`
`ENSRRO1 AY CHOK, SM—-1349 6R5HOFSSRORRBIT
`
`PERE CIRCbok, PHI, BATHE, PERTH, PERRET.
`
`FREELY DILDO,
`
`10
`
`Ci i) _LACaS LIARREAR C88) ON KEBBRASHRTS Pal OORT,
`
`
`
`
`
`ES SARBRAAME ()
`
` SAREOS
`
`ithBor
`
`#HG6IRANSEBRY, PILAR, SM-13496 40mg, 120mg
`
`REHCENEHN API, 3H, 2A ERRABERONE, WPM
`
`TRERAK ¢ ORRERILBE SAE,
`
`15
`
`Ci
`
`i i) Ee, ARAMACHO OALCRIPEA& Pade 7 ICART.
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 011
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 011
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`11
`
`use
`
`HE
`
`q
`
`ee
`
`i)~~
`
`~—
`
`ry
`
`—_~doVs
`
`So
`
`e
`
`osOo=
`
`—i)~
`
`
`
`
`
`
`
`
`
`Pipes|fw50 fw7 [9“49 |
`
`
`
`
`
`eS
`—
`
`
`Wb DIRE
`]
`2—™~|oNEPo™ /o;o!]oSS|oja
`:>oa
`
`ePlo!lo}co
`mempfe1S|
`
`po[Re|p
`mm|aNoO|owa[mo
`o|o
`HERR
`mmloo:—
`ro}Oo[re
`
`ws|™/o|oNee
`oDLo|So—|e
`mmONnw;uwfNw
` ;o|o
`Re|e
`
`He7a
`
`
`
`
`
` in
`
`
`
` veOaHu
`
`
`
`
`|
`
`HFRS
`1 2)
`0 (0)
`Oe
`
`
`|PRGRS Ae
`
`
`
`
`
`
`
`
`
`
`
`
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 012
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 012
`
`

`

`Ba Dee
`
`BIE EV)
`(TlHERca @ BR < )
`
`ie
`
`etwas
`
`ERA
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 013
`
`WO 2004/017973
`
`PCT/JP2003/010490
`
`12
`
`iS
`
`1 F B
`
`K
`
`Be
`
`jee
`
`
`
`
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 013
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`
`
`
`
`MmpAIvyFYy + RA
`AREIM
`
`WS BM
`
`
`
`
`
`
`
`
`
`
`
`RTICRENSEBY, GEFROIL, SM—-13496R5LORREK
`
`SBECE RWER DO (BERD IL, FR, IER, TOYVT, SPEDE
`
`(EISMERCeR <). UR, BRR Choe, SM-1349685HCYA=X
`
`5
`
`— DFFLBSITED? 2 fe (4YAH),
`
`1 2 PRELUDE TIS C HRAICEEBEO SH
`
`PALITFIR7, RRARRB eR LEBSORAICSREC
`
`RERBLRDOK SM—-13496R5HCHSEROMPT AFI FU
`
`DEO OCA. Ni, MFR. AERAUSERATDAGGERCISPRERR
`
`ies & APTIOND,
`
`10
`
`(iv) SBI, HEASHRIERChAVAYRVT(AIMSIZES), FHIYYT
`
`(BASIZES), AH YY VEER(SA SILKS)OPPMOGRER 8 (TAT,
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 014
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 014
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`Fz 8
`
`14
`
`
`
`
`
`
`
`
`AVAWRBE mz (sp)|324) (SD) Ez) (SD)
`
`
`
`AIMS
`0.7 (2.63)
`0.7 (2. 88)
`0.2 (2.21)
`
`
`
`
`
`~0.1 (0.96)|0.1 (1.08)|0.588|0.1 (1.11)|0.808
`
`
`
`#: TERIAAy htRE (BAB LS eR L OLR)
`
`Wi, BORAT. RSA HEEL LEEDROT
`
`*: SEHAayiIZoxn=44~47
`ek: BAS Aa AVAIL
`
`XE SICHESNSRROSM SPRL, REMPOOAZIAYNAMA IT
`
`OPEBSA CoHSMICABREED bNRPok, ~vAbREY
`
`BYE L LEBAIXSM—13 49 ORE C2 4%, SAFURREHTI 8%
`
`Cho%K.
`
`pose LOAAATABLE
`
`ARIS OREAAVEDIPRAIEB LOSTAV SIARAIIL, HEPELAWO
`
`(1R,2S,3R,4S)—-N-[(1R,2R)—2-[4-(1, 2-"Y YA VFS
`
`10
`
`Yor 8-4) — LH ER FVENV AFNI - LAY BNIRAFI] —
`
`2,8-EY7 (2. 2. 1IAAPYVINREFD PERME ORSLAA
`
`SiS, PICOMERTMARHED BAIUCLA LERORSEST
`
`SrUICKO, AVHRR REA OPED CO ER<, BRR, MEEK,
`
`AMER: CIRieee, CS CGPI£ OREROCIEI
`
`15
`
`SRR L. ERICPDS DBM CIEE © SHER ZS LORD OIL
`
`72), HD CREIHAT SOLS CE, RRRORSGITDIBL, S 6 ICSat
`
`ILbRBICAVEBS ED, EDD CENKIRRATIES LOBRAl CHS.
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 015
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 015
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`1. BAREBSOWRDCho Tt, TEHEKAwEELTHK(1):
`aq
`OH
`
`
`ee
`Tits
`Ho
`
`(1)
`
`N ors
`.
`=
`SH A
`
`Ny
`N
`/
`N-Z S
`N
`'*“N
`
`CRAEMS(1R,25,38R,48S)—-N-[(1R, 2R)-—2-[4-(1, 2-~v
`
`SHA VFIF LN 8-4 NM) 1K ERG VENAFNV) - 1-7 ane
`
`RFMVI—2,3-EY7 a2. 2. 1]NFRPVVONHA TY2 PERHMtOR
`
`EAA SN OMe LARGER ome~1 20mg C1 AL MRARSSSCL
`
`(CLOT, PEASERIVER OPELAED MERC. PRRAELIBIG SK,
`
`10
`
`2. HtEbawA, (1R,2S,3R,4S)-N-[(1R, 2R)—2-[4—-(1,
`
`2—-RY YA VFI TYHN 8B -AN) HL HER FVaNAFN)-1-Yr7u
`
`AKUVAFN]—2,3 -EV7H[2.2.1INPRYVANWR2 EE
`
`taCd SFR 1 (CARO WARK,
`
`3. BEAARMED VEER EET 6 PR 1 EVIL 2 CHMOD,
`
`15
`
`4. ReAREOBMIEKS kOBRERE EET SFPRE 1 EK 2 ICRAMO
`
`RATE.
`
`5. WMMKGWO(1LR,2S,3R,4S)-N—-[(1R, 2R)—2-[4-(1, 2
`
`RAYS AVFFSV 38 -4A NM)-A KH ERP VENRAFI)-1-yg as
`
`HYMAFNVI]-2,38-ECv7al[2.2.1InARVYVAN4 S PR
`
`20
`
`eLARSB2 Omeg~8 Omg 1A 1 AROSST SIR 1 EK
`
`MOWAT
`
`6. PARTEORE EET 5 AR 5 IRROAK,
`
`7. BEARRHEO BPRS L UBER 2 CET SR 5 ITEROAY,
`
`8. EERIORAARIEOIGROTIECho TC. MEERWO(1R,2S8,3R,4
`S)-N—[(1R,2R)—2—[4—(1, 2-AYYR VFTY—N- 8-4 0)
`—LHERFVANVA FN) - 1 HONEA FN)—-2,39-EFe7e[e2.
`
`25
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 016
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 016
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`16
`
`2.1INTFYVYANHRAT4 > PRR LARSBS me~8 Ome C1A
`
`LARORSTSOLITL OT, GEASHRRBIER OPREEHS OLR. RE
`
`AME KEES SHAR L Eick 2 CAMO,
`
`9. RiaORE CET SAC 8 ITEROIE,
`
`10. MAAHEOBMERS LOBHHERE RET SRE 8 ICRROIRA
`
`1k,
`
`11. We(KeWO(1R,2S,3R,4S)—-N-[(1R, 2R)—-2-[4—-(1,
`
`2—-AYV SA VFTSN 8-H LOH ER PYaN AFN-1L-Y7u
`
`NEYAFW]—2,38-EVY AQ. 2.1InRAPRVVINX 2 SB
`
`10
`
`ie 1 ARSE 1 Omg~40meg C1 1 RORSTARS ICHROU
`
`ROT.
`
`12. BAARORMIER CUES SRA 1 1 CHROIRO,
`
`13. MeATEOBMHERS LOBHER SUGEEST SR 1 1 (CHRO
`
`Fiitk.
`
`15
`
`14. Ekewe UTH(1) :
`<c——=
`
`H
`
`.
`J Ny’
`
`Ho
`=
`Tlir
`
`é
`\
`Ny
`=e—N N-" 'S
`H H
`\_/
`
`;
`
`(1)
`
`CRENS(1R,2S,3R,48S)-N-[(1R,2R)—2—-[4-(1, 2-~v
`
`SA VFIFT SN 8-4) - 1H ERG VEN AFIN) - 1-Hane
`
`AFMVI]—2,383-EVI7a[2. 2. UANAPRVYVANE 2 PERMEOER
`
`20
`
`REAASNSe LAL ERORSRE LCome~l 20mg SA ahis
`
`WE OVA,
`
`15. Weke@wA, (1R,2S,8R,48S)-N-[(1R, 2R)-2-[4-
`
`(1, 2-RYY 4 VF TYN38 - 4) - 1H URS VEaNAF) -1-Y
`
`DAUNEYMAFNV]—2,8-EV7EL2. 2. 1InRGRVVNREVI TE
`
`25
`
`HAMSCd SAAR 1 4 CHRROIARA
`
`16. WHILAwWOGAES 2 Ome~8 Omg CHSMREAIAERIZISK
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 017
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 017
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`17
`
`ECROIARA,
`
`17. (1):
`
`#49i Qn N.
`
`
`[ft
`Ho
`
`SiarNT?
`
`(1)
`
`CRENS(IR, 25,38R,4S)-N—-[(1R, 2R)—-2-[4—-(1, 2-“~v
`
`DAVFIF YN 8 -A NM) LH ERG VaR FN) - LHI BAN
`
`AFW)—2,38-Cv7a[2. 2.1 AASPVVANES YA PERIMCOR
`
`3KLEPA SPN ABOMARMEIARAL SMELT SOOKE,
`18. WMekewas, (1R,25S,3R,4S)-N-[(1R, 2R)—-2-[4-
`
`(1, 2-—RY SAV FTSN 38 -ANM) HLH ERG VENAFNI-1—-Y
`
`10
`
`DANEYUWVAFN)—-2, 8-EVAual2. 2.1]InAFFVYVANREP
`
`SMSC db SFR 1 7 CLOEAL
`
`
`19. BEAESRAIDISHMLAwe 1 LEA RSELt LUC omg~l1 2
`
`Omg StS, MORAL 7 ERIE 8 (CHRO,
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 018
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 018
`
`

`

`WO 2004/017973
`
`PCT/JP2003/010490
`
`1/1
`
`4 1
`
`
`
`
` —O— Foe (n=49)
`—m— SM-13496 40 mg“ (n=49)
`—O— SM-13496 120mg’ (n=47)
`
`
`
`4 4 8
`
`+10
`
`12
`
`
`
`ZAPORPHYEIL
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`Byles)
`
`(sled)
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 019
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 019
`
`

`

`INTERNATIONAL SEARCH REPORT
`
`International application No.
`PCT/JP03/10490
`
`A. CLASSIFICATION OF SUBJECT MATTER
`Int.Cl’ A61K31/496, A61P25/18//C07D417/12
`
`According to International Patent Classification (IPC) or to both nationalclassification and IPC
`
`B. FIELDS SEARCHED
`Minimum documentation searched(classification system followed by classification symbols)
`Int.Cl’ A61K31/496, CO7D417/12
`
`Documentation searched other than minimum documentation to the extent that such documentsare included in the fields searched
`
`Electronic data base consulted during the international search (name ofdata base and, wherepracticable, search terms used)
`CAOLD (STN)
`REGISTRY (STN), CAPLUS (STN),
`
`C.fC.CONSIDEREDTOBERBLEVANTsssssisi‘“‘“(‘“(C;*™*rDOCUMENTS CONSIDERED TO BE RELEVANT
`
`
`
`"Relevant to claim No.
`Category*
`Citation of document, with indication, where appropriate, ofthe relevant passages
`08 January, 1992
`LID.),
`EP 464846 Al
`(SUMITOMO PHARMACEUTICALS CO.,
`(08.01.92),
`Full text; particularly,
`lines 29 to 34
`& JP 05-017440 A
`& CA 2046429 A
`
`(101); page 13,
`
`& US 5532372 A
`
`14-19
`
`(SUMITOMO PHARMACEUTICALS CO.
`
` compound
`
`WO 02/24166 Al
`LTD.),
`(28.03.02),
`28 March, 2002
`Full text; particularly,
`examples
`& AU 2001086237 A
`& BP 1327440 Al
`
`LC] See patent family annex.
`[_] Further documentsare listed in the continuation ofBox C.
`“T”—later documentpublished after the internationalfiling date or
`Special categories of cited documents:
`priority date and not in conflict with the application but cited to
`documentdefining the generalstate of the art which is not
`considered to be of particular relevance
`understand the principle or theory underlying the invention
`documentofparticular relevance; the claimed invention cannot be
`earlier documentbut published on orafter the internationalfiling
`date
`considered novel or cannot be considered to involve an inventive
`step when the documentis taken alone
`document which may throw doubts on priority claim(s) or which is
`documentofparticular relevance; the claimed invention cannot be
`cited to establish the publication date of anothercitation or other
`considered to involve an inventive step when the documentis
`special reason(as specified)
`combined with one or more other such documents, such
`documentreferring to an oral disclosure, use, exhibition or other
`means
`combination being obvious to a person skilled in the art
`document memberof the same patent family
`
`“ye
`
`“yr
`
`documentpublished priorto the internationalfiling date but later
`than thepriority date claimed
`Date of the actual completion ofthe international search
`25 November, 2003 (25.11.03)
`
`Date of mailing ofthe international search report
`16 December, 2003 (16.12.03)
`
`Name and mailing address of the ISA/
`Japanese Patent Office
`
`Facsimile No.
`
`Form PCT/ISA/210 (second sheet) (July 1998)
`
`Authorized officer
`
`Telephone No.
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 020
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 020
`
`

`

`INTERNATIONAL SEARCH REPORT
`
`International application No.
`PCT/JP03/10490
`
`Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
`This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
`
`1.
`
`Claims Nos: 1 to 13
`
`2. [| Claims Nos.:
`becausetheyrelate to parts ofthe international application that do not comply with the prescribed requirements to such an
`extent that no meaningful international search can becarried out, specifically:
`
`3. [| Claims Nos.:
`because they are dependentclaimsandare not drafted in accordance with the second and third sentences of Rule 6.4(a).
`
`Box II Observations whereunity of invention is lacking (Continuation of item 3 of first sheet)
`
`,
`
`This International Searching Authority found multiple inventions in this international application, as follows:
`
`1, [| As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
`claims.
`
`2. [| Asall searchable claims could be searched without effortjustifying an additional fee, this Authority did not invite payment
`of any additionalfee.
`
`3. [| As only someofthe required additional search fees were timely paid by the applicant, this international search report covers
`only those claims for which fees were paid, specifically claims Nos.:
`
`because theyrelate to subject matter not required to be searched bythis Authority, namely:
`Claims 1 to 13 pertain to methods for treatment of the human body by surgery
`or therapy andthus relate toa subject matter which this International Searching
`Authority is not required to search.
`
`[| No protest accompanied the paymentofadditionalsearch fees.
`
`4. [| No required additional search fees were timely paid by the applicant. Consequently, thisinternational search report is
`restricted to the inventionfirst mentioned in the claims; it is covered by claims Nos.:
`
`Remark on Protest [|
`
`Theadditional search fees were accompanied by the applicant’s protest.
`
`Form PCT/ISA/210 (continuation offirst sheet (1)) (July 1998)
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 021
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 021
`
`

`

`A. ®SHOBTS7HODR (BRO (1 PC) )
`
`ESieeetay
`
`PSHE PCT/IP03/10490
`
`Int. C17 A61K31/496, A61P25/18 // COTD417/12
`
`B. Wee ToORDe
`HaeTokeMRA RTO CI PC) )
`
`Int. Cl’ A61K31/496, CO7D417/12
`
`Re/MRASLDAORSCHE E172 KDHE ENS BO
`
`BURMACR LRPIAP AHA (FHAAOAA, REICH Lc
`
`REGISTRY (STN), CAPLUS (STN) , CAOLD (STN)
`
`aee te
`|
`
`Dray—x|
`
`X
`
`X
`
`BAH, ROCOMOMPREET SL x1, OMT SORE
`
`
`(SUMITOMO PHARMACEUTICALS COMPANY, LIMITED)
`
`EP 464846 Al
`1992. 01. 08
`BX. IEA (101) RO1 3R29~3 47S
`&JP 05-017440 A &US 5532372 A &CA 2046429 A
`
`(FEACERIRERELS4L) 2002. 03. 28
`WO 02/24166 Al
`BX, HICHPIBAR
`&EP 1327440 Al &AU 2001086237 A
`
`
`
`
`
`
`
`AROTOBE
`
`14-19
`
`14-19
`
`
`[J Cilogee cb RMA NTS.
`[L] AFv br SIMMSSREB.
`* BIRCRODFT TY
`OH OGIAH SNE
`(A) RICBREOSIMCHAS OT) BPR ISB RITARSNEMMTCHOT
`bO
`HLFETS bO CSE <. BAOREML
`TE) ESHER BIO HRS ceCSD, ERE
`DEROEOIZUATSbO
`DECAREHEDO
`IX) FCPOD SMKChHoC, SROCKOSCEH
`TL) GEFSHESSRITHERS EEETB OCHREALDMROAGT
`DSTFAPERITHEBED RAV LBA SNSSO
`Aa Le LORRIERT SE DISIETS
`TY) BOSS MRCHOT, SROCHL HOLY
`SRK GER eH)
`LOXREO, SHRI Lo CHAChH SMetI
`[O] ARRIC KSB, A, BRECERT SMM
`Loa CHEBEBRVEBZSNSLO
`IP) ERMA ATC, DORHOTFRORML SHR [&) AAT Yb 7 7 RY 3
`
`
`
`HPSe5eT LA
`PAA368 A
`25.11. 038 16.12.03
`
` [a7]p05
`KRTHE (HIRO SIR) zo
`
`
`EAR OLRRUS CH
`Ae}SAG
`A P=
`
`RABBIT (CISA/J P)
`
`
`TPES 100-8915
`Bee 03-3581-1101 Am 3492
`
`RRATRERBSHLTAAB3
`
`
`
`HERPCT/ISA/210 (B2x-Y)
`(1998474)
`
`
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 022
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 022
`
`

`

`ERAS
`
`BMWSS PCT/JPO03/10490
`
`Ligiro fe,
`
`PROM 1~1 BILENITRIC LEAKOMBAEROPTIECH, COE
`PISARRRBA 4m LEE LAVMBILRS EO CHS,
`
`tk, AEB RARMAETS LM Ck CREE CHEOBFEMKLTYY
`MRO
`7PV IREOMAITHRS BOCHS, DEY,
`
`2RORH
`Fito CHR S IVT),
`
`Ik, RBAPROGH CH oT PC THUG. 4(a) OH 2 LRU 3 KOMEI
`
`A OM—PEBARML CWS LEORE 1X VO 3 ORE
`
`RIAD LOCI OBB IULORBARHS L-OBBMMBARBTROL.
`
`SS Hl FROG O—-MOMEA CARY LEORE GB1X- VO 2 OE)
`BH SARI (PCT 17RDG)) CREED. <ORMEARORAEY REROROBICOCH
`1. k] HRoOgEH
`1-13
`ik, — ORRARMBMAETS IL EBLRVWRILRS OCHS,
`DED,
`
`[] sSOUBAAS=ERCSNet & RIC BLAa © ARERR ECARDTe
`
`AaERSTSCAH LOC, CORDA, TC ORBITER
`OPI OVYC HERR Lice
`. () RNAAEEBLEBERTSE CHES. FAC OMAROMITOVCHET S IER TEROT, JB
`ANFAZSEPBBOAH BRD PBA Te
`
`BAReeePESeROA LORAIN LADOKOTC, CORDHEREIL SEO
`MO t aICROPBROHA OAC OV THER Leo
`
`EJ HRADABEEACESIAC LADO LOC, CORPREIL, APROMGAORMICA
`SIVTW A ASAITAR RORO HA ICOVV CHER LZ.
`
`INEFREORRO Hicict SER
`(] JE01RSBORLOMACEIDb RMAC Rb ore,
`
`MSRP CT/ISA/210 (81%-VOwBE (1) )
`
`(1998478)
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 023
`
`Par Pharm., Inc.
`Exhibit 1019
`Page 023
`
`